Survival

VIPoma is a type of neuroendocrine tumour (NET) that usually starts in the pancreas. Survival for VIPomas depends on many factors. So you should only use these statistics as a guide.

Doctors usually work out the outlook for a certain disease by looking at large groups of people. Because VIPomas are rare tumours, the survival of this disease is harder to estimate than for other, more common cancers.

These are general statistics based on small groups of people. Remember, they can’t tell you what will happen in your individual case. Your doctor can give you more information about your own outlook (prognosis).

You can also talk about this with the Cancer Research UK nurses on freephone 0808 800 4040, from 9am to 5pm, Monday to Friday.

What affects survival

Survival depends on many factors. It depends on the stage and grade of the tumour when it was diagnosed. The stage describes the size of the tumour and whether it has spread. The grade means how abnormal the cells look under a microscope.

Another factor is how well you are overall. 

Survival for VIPomas

There are no survival statistics for VIPomas. It is difficult to collect data because VIPomas are so rare.

An American study looked at the average length of time from either diagnosis or treatment, that people with VIPoma lived for. This is called overall survival. Please be aware that due to differences in health care systems, data collection and the population, these figures may not be a true picture of survival in the UK. This study was also done some time ago and people are now more likely to have different and better treatments.  

This study found that people with VIPoma live about 8 years on average after being diagnosed. This means that a lot of people with VIPoma live for 8 years or more. 

Survival for NETs of the pancreas

In the UK, no statistics are available for the survival of all the different types of pancreatic NETs. This is because researchers haven’t collected this information yet. The information we have here is the 1 year survival for all types of pancreatic NETs.

This information is from people diagnosed in England between 2013-2015. Because this is for England only, it might not be the same for the whole of the UK.

Around 80 out of every 100 people (80%) diagnosed with a pancreatic NET survive for 1 year or more. 

About these statistics

The term 1 year, 5 year and 10 year survival does not mean that you will only live for 1, 5 or 10 years. They relate to the number of people who are still alive 1 year, 5 years or 10 years after their diagnosis.

Some people live much longer than 10 years.

What next?

You might want to read our information about treatment for VIPomas.

Last reviewed: 
18 Jun 2019
  • Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
    T Halfdanarson and others
    Annals of Oncology, 2008. Vol 19, Pages 1727-1733

  • 1-Year survival rates for neuroendocrine tumour patients in England
    T Genus and others
    Public Health England, 2017

  • Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes
    C Roland and others
    Journal of Surgical Oncology, 2012. Vol 105, Issue 6, Pages 595-600

  • VIPoma: Clinical manifestations, diagnosis, and management
    Emily Bergsland
    UpToDate, Accessed May 2018

Related links